Robinson, Brian D.
Vlachostergios, Panagiotis J.
Bhinder, Bhavneet
Liu, Weisi
Li, Kailyn
Moss, Tyler J.
Bareja, Rohan
Park, Kyung
Tavassoli, Peyman
Cyrta, Joanna
Tagawa, Scott T. http://orcid.org/0000-0003-2777-8587
Nanus, David M.
Beltran, Himisha
Molina, Ana M.
Khani, Francesca
Miguel Mosquera, Juan
Xylinas, Evanguelos
Shariat, Shahrokh F.
Scherr, Douglas S.
Rubin, Mark A. http://orcid.org/0000-0002-8321-9950
Lerner, Seth P.
Matin, Surena F.
Elemento, Olivier
Faltas, Bishoy M. http://orcid.org/0000-0002-6432-1693
Funding for this research was provided by:
American Society of Clinical Oncology
Article History
Received: 18 April 2018
Accepted: 4 June 2019
First Online: 5 July 2019
Competing interests
: B.D.R. has received consulting fees from BMS, S.T.T. received honoraria from Janssen. D.M.N. served on the data safety monitoring board for Genentech and Roche. H.B. has received research funding from Janssen, Abbvie/Stemcentryx, Astellas, Eli Lilly, Millennium and has served as advisor/consultant for Janssen, Astellas, Amgen, Astra Zeneca, Sanofi Genzyme. S.T.T., D.M.N., A.M.M., and B.M.F. has received research funding from Janssen for Weill Cornell Medicine for clinical trials. E.X. is a consultant for Janssen. S.F.S. has received honoraria, consulted or served on advisory boards for Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, Ipsen, Janssen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Richard Wolf Roche, Sanochemia, Sanofi, Takeda, Urogen. S.P.L. research funding for clinical trials from Endo, FKD, JBL (SWOG), Roche/Genentech (SWOG), UroGen, Viventia and is consultant for Archiano Therapeutics, UroGen, Vaxiion. S.P.L. is on the advisory board of Archiano Therapeutics, Ferring, miR Scientific, QED Therapeutics, UroGen. S.F.M. is a consultant for QED Therapeutics. B.M.F. has received research support for Weill Cornell from Eli Lilly. The remaining authors declare no competing interests.